Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Novel Targets of Interest in EC

June 4th 2021

Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.

PFS Improved With Niraparib Maintenance in BRCA+ Ovarian Cancer

June 4th 2021

Maintenance therapy with niraparib significantly improved progression-free survival in patients with BRCA-mutated ovarian cancer, according to results from three phase 3 trials.

Insight on Ongoing Trials in EC

June 4th 2021

Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.

Incorporating Molecular Features into Choosing Adjuvant Therapy

June 4th 2021

Experts discuss the importance of incorporating molecular features into the selection of adjuvant treatment.

Therapeutic Sequencing in Endometrial Cancer

June 4th 2021

Experts in endometrial cancer comment on therapeutic sequencing in endometrial cancer.

Adjuvant Chemotherapy Fails to Improve PFS and OS in Locally Advanced Cervical Cancer

June 3rd 2021

The administration of adjuvant carboplatin and paclitaxel following standard cisplatin-based chemoradiation failed to demonstrate an improvement in progression-free survival or overall survival in women with locally advanced cervical cancer, according to findings from the phase 3 OUTBACK trial.

Managing AEs With Pembrolizumab and Lenvatinib

June 1st 2021

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.

Experience in Using Pembrolizumab + Lenvatinib in Advanced Endometrial Cancer

June 1st 2021

Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.

Dr. Chern on Future Research Directions in Ovarian Cancer

May 25th 2021

Jing-Yi Chern, MD, ScM, discusses future research directions in the treatment of patients with ovarian cancer.

A Discussion on the Study 309/KEYNOTE-775 Data

May 25th 2021

Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.

Results from Study 309/KEYNOTE-775

May 25th 2021

Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.

Screening, Vaccination Guidance May Be Responsible for Decline in HPV-Related Cervical Cancer

May 19th 2021

Evidence from a population-based study on the incidence of human papillomavirus–related cancers indicate a marked decline in cervical carcinoma, potentially due to clear guidance regarding screening measures and HPV vaccination for vulnerable patient groups.

Dr. Johnson on Racial Disparities in Outcomes Across Multiple Tumor Types

May 19th 2021

Anita Johnson, MD, FACS, discusses racial disparities in outcomes across multiple tumor types.

Novel Combinations for the Treatment of Advanced EC

May 19th 2021

Experts in gynecologic oncology discuss novel combination strategies for the treatment of advanced endometrial cancer.

Emerging Data From Ongoing IO Combination Trials in EC

May 19th 2021

Shannon N. Westin, MD, MPH, FACOG, and Vicky Makker, MD, comment on data from ongoing clinical trials presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer for the management of advanced endometrial cancer.

Study 309/KEYNOTE-775 Trial Design

May 18th 2021

Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.

Therapeutic Approaches in Endometrial Cancer

May 18th 2021

Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.

Cemiplimab Reduces Risk of Death by 31% Vs Chemotherapy in Advanced Cervical Cancer

May 13th 2021

The PD-1 inhibitor cemiplimab resulted in a 31% reduction in the risk of death compared with chemotherapy in patients with recurrent or metastatic cervical cancer who have progressed on chemotherapy.

Patient Selection for Lenvatinib-Pembrolizumab for Advanced EC

May 12th 2021

Experts in gynecologic oncology share insights on patient selection for lenvatinib-pembrolizumab in advanced endometrial cancer and discuss therapeutic sequencing through multiple lines of therapy.

Impact of Lenvatinib-Pembrolizumab on Clinical Practice in Advanced EC

May 12th 2021

Vicky Makker, MD, and Shannon N. Westin, MD, MPH, FACOG, discuss their experiences using lenvatinib-pembrolizumab therapy for advanced endometrial cancer.